OPR - Delayed Quote • USD SNN Sep 2024 25.000 call (SNN240920C00025000) Follow 1.7000 0.0000 (0.00%) At close: April 5 at 10:35 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for SNN240920C00025000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: SNN With 83% ownership of the shares, Smith & Nephew plc (LON:SN.) is heavily dominated by institutional owners Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia Here’s Why You Should Invest in Smith & Nephew plc (SNN) Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE) Investors five-year losses continue as Smith & Nephew (LON:SN.) dips a further 5.6% this week, earnings continue to decline Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds Smith & Nephew PLC's Dividend Analysis Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital 7 Robotic Surgery Stocks to Buy for the Future of Healthcare Smith & Nephew plc Just Missed EPS By 38%: Here's What Analysts Think Will Happen Next
